Neonatal screening for isovaleric aciduria: Reducing the increasingly high false‐positive rate in Germany

Newborn screening (NBS) for isovaleric acidemia (IVA) is performed by flow injection tandem mass spectrometry quantifying C5 carnitines (C5). Isovalerylcarnitine, however, is isomeric with pivaloylcarnitine which can be present in blood due to maternal use of pivaloylester‐containing antibiotics, available in Germany since late 2016. During a 36‐month period (January 19–December 21), all newborns screened in Hamburg with a C5 above cutoff (NeoGram®: 0.50 μmol/L or Neobase®2: 0.45 μmol/L) were included in the study. As a second‐tier test, a simple ultra performance liquid chromatography‐tandem mass spectrometry (UPLC‐MS/MS) method was developed to differentiate the C5 isomers pivaloyl‐, 2‐methylbutyryl‐, isovaleryl‐, and valerylcarnitine. Out of 156 772 newborns tested, one turned out to have genetically proven IVA while 99 were false positive (C5: 0.5–8.2 μmol/L) due to the presence of pivaloylcarnitine. These cases have increased year by year and show local clusters. Retrospective analysis of another 39 cases from 287 206 neonates tested at the NBS center in Heidelberg with C5 elevation (0.9–10.6 μmol/L) but clinical and biochemical exclusion of IVA yielded evidence of pivaloylcarnitine in all cases. Inclusion of a second‐tier test into NBS significantly reduces the high and increasing false‐positive rate of IVA screening. This avoids further diagnostic steps, prevents unnecessary stress and anxiety of parents in a remarkably high number of cases. If Hamburg data of 2021 are extrapolated to all of Germany, one can assume around 800 (1‰) false‐positive cases in comparison to an average of two classic IVA cases per year. Unless licensing of pivaloylester‐containing drugs for use during pregnancy is reconsidered, a second‐tier test for C5 determination is indispensable.

[1]  S. Grünert,et al.  Newborn screening and disease variants predict neurological outcome in isovaleric aciduria , 2021, Journal of inherited metabolic disease.

[2]  D. Hougaard,et al.  Raising Awareness of False Positive Newborn Screening Results Arising from Pivalate-Containing Creams and Antibiotics in Europe When Screening for Isovaleric Acidaemia , 2018, International journal of neonatal screening.

[3]  C. Hoppel,et al.  Selective and accurate C5 acylcarnitine quantitation by UHPLC-MS/MS: Distinguishing true isovaleric acidemia from pivalate derived interference. , 2017, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[4]  K. Naber,et al.  Epidemiologie, Diagnostik, Therapie, Prävention und Management unkomplizierter, bakterieller, ambulant erworbener Harnwegsinfektionen bei erwachsenen Patienten , 2017, Der Gynäkologe.

[5]  S. Fukuda,et al.  Clinical Features of Carnitine Deficiency Secondary to Pivalate-Conjugated Antibiotic Therapy. , 2016, The Journal of pediatrics.

[6]  Y. Hasegawa,et al.  Elevation of pivaloylcarnitine by sivelestat sodium in two children. , 2015, Molecular genetics and metabolism.

[7]  U. Steuerwald,et al.  UPLC-MS/MS analysis of C5-acylcarnitines in dried blood spots. , 2013, Clinica chimica acta; international journal of clinical chemistry.

[8]  J. Bonham Impact of new screening technologies: should we screen and does phenotype influence this decision? , 2013, Journal of Inherited Metabolic Disease.

[9]  R. Fingerhut,et al.  Newborn screening for isovaleric acidemia using tandem mass spectrometry: data from 1.6 million newborns. , 2011, Clinical chemistry.

[10]  E. Clayton,et al.  False Positive Newborn Screening Results Are Not Always Benign , 2010, Public Health Genomics.

[11]  S. Palmer,et al.  Rapid determination of C4-acylcarnitine and C5-acylcarnitine isomers in plasma and dried blood spots by UPLC-MS/MS as a second tier test following flow-injection MS/MS acylcarnitine profile analysis. , 2010, Molecular genetics and metabolism.

[12]  S. Krähenbühl,et al.  Interaction between pivaloylcarnitine and L-carnitine transport into L6 cells overexpressing hOCTN2. , 2009, Chemico-biological interactions.

[13]  S. Waisbren,et al.  A review of the psychosocial effects of false-positive results on parents and current communication practices in newborn screening , 2006, Journal of Inherited Metabolic Disease.

[14]  N. Chamoles,et al.  Diagnosis of isovaleric acidaemia by tandem mass spectrometry: False positive result due to pivaloylcarnitine in a newborn screening programme , 1998, Journal of Inherited Metabolic Disease.

[15]  K. Isselbacher,et al.  Isovaleric acidemia: a new genetic defect of leucine metabolism. , 1966, Proceedings of the National Academy of Sciences of the United States of America.

[16]  J. Bonham,et al.  Introduction of a Simple Second Tier Screening Test for C5 Isobars in Dried Blood Spots: Reducing the False Positive Rate for Isovaleric Acidaemia in Expanded Newborn Screening. , 2018, JIMD reports.

[17]  F. Debray,et al.  Surprising causes of C5-carnitine false positive results in newborn screening. , 2014, Molecular genetics and metabolism.